Eisai and Glenmark settlement over generic version of Banzel

1 May 2015
medical_legal_law_big

Japanese drug major Eisai (TYO: 4523) has entered into a settlement agreement with Indian drugmaker Glenmark Pharmaceuticals (BSE: 532296) and its US subsidiaries to resolve their patent litigation relating to Eisai's Banzel (rufinamide) in the USA.

As a result of the settlement, or pay-for-delay deal, Glenmark will be permitted to market a generic version of Banzel in the USA on May 30, 2022, or potentially earlier under certain circumstances. Additional terms of the settlement agreement are confidential.

Banzel is an anti-epileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children aged one year and older and adults.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics